Eflornithine to Prevent Cancer in Patients With Barrett's Esophagus

Completed · Phase 2

Conditions studied: Esophageal Cancer

In brief

RATIONALE: Chemoprevention therapy is the use of drugs to try and prevent the development or recurrence of cancer. It is not known whether eflornithine is effective in preventing cancer in patients with Barrett's esophagus. PURPOSE: Randomized double-blinded phase II trial to study the effectiveness of eflornithine in preventing cancer in patients with Barrett's esophagus.

Key facts

Study ID

NCT00003076

Run by

University of Michigan Rogel Cancer Center

People needed

152

Starts

1995-10-01

Expected to finish

2005-10-01

Last updated by the study team

2012-12-19

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

• Tulane University School of Medicine — New Orleans, Louisiana, United States
• Massachusetts General Hospital Cancer Center — Boston, Massachusetts, United States
• University of Michigan Comprehensive Cancer Center — Ann Arbor, Michigan, United States
• Arthur G. James Cancer Hospital - Ohio State University — Columbus, Ohio, United States
• Veterans Affairs Medical Center - Dallas — Dallas, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.